Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kathleen Large | F | 64 | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Edward A. Taylor | M | 81 |
Biomira, Inc.
 Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 13 years |
| Niclas Stiernholm | M | - | 8 years | |
| David Allan | M | 82 | 3 years | |
| Christopher Henney | M | 83 |
Xcyte Therapies, Inc.
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 2 years |
| Jan Skvarka | M | 57 | 2 years | |
| W. Vickery Stoughton | M | 78 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 18 years |
| Dan Spiegelman | M | 65 |
Xcyte Therapies, Inc.
| 14 years |
| Calvin Stiller | M | 83 | 8 years | |
| Laurence Jay Korn | M | 74 |
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 16 years |
| Thomas Reynolds | M | 65 | 7 years | |
| Mary Fenton | F | 60 | 4 years | |
| Kathi Cordova | F | - |
Xcyte Therapies, Inc.
| - |
| Joanna S. Black | F | - |
Xcyte Therapies, Inc.
| - |
| Cameron Wheeler | M | 45 | 5 years | |
| Helena Tayton-Martin | M | 57 | 4 years | |
| Spencer Nam | M | 55 | 4 years | |
| Diana Hausman | M | 61 | 7 years | |
| T. McPherson | M | 85 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 15 years |
| Jaisim Shah | M | 63 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 6 years |
| Briggs Morrison | M | 65 | 5 years | |
| R. Rao Koganty | M | 81 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 22 years |
| Paolo Pucci | M | 63 | 1 years | |
| Steven James | M | 66 | 3 years | |
| Paul Walker | M | 49 | 1 years | |
| Julia Eastland | F | 59 | 8 years | |
| Shashi Karan | M | 70 | 2 years | |
| Stephen Harbin | M | 66 | 3 years | |
| R. Dean Peterson | M | - | 4 years | |
| Michael G. Moore | M | - | 7 years | |
| Ted Love | M | 65 | 5 years | |
| Michael Kamarck | M | 73 | 1 years | |
| Joanna Lin Black | F | - |
Xcyte Therapies, Inc.
| 3 years |
| Rosemary Harrison | M | 41 | 1 years | |
| Eric Rubin | M | 65 | 2 years | |
| D. Kirkpatrick | M | 67 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 2 years |
| Douglas Williams | M | 66 | 4 years | |
| Luke Beshar | M | 65 | 7 years | |
| Michael C. Welsh | M | 81 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 21 years |
| James DeMesa | M | 66 | 9 years | |
| Scott Myers | M | 57 | - | |
| Bill Wickson | M | - |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | - |
| S. Robert Blair | M | - |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 1 years |
| Jay Venkatesan | M | 52 | 1 years | |
| Benjamin Looker | M | 42 | - | |
| Abdelmalik Slassi | M | 62 | 3 years | |
| Scott Robert Peterson | M | 62 | 9 years | |
| Yaping Shou | M | - | 2 years | |
| Gwen A. Fyfe | M | 72 | 2 years | |
| Brian Jahns | M | - | - | |
| David Shin | M | - | 2 years | |
| Ingmar Bruns | M | 49 | 1 years | |
| Chris Hoel | M | 52 |
Xcyte Therapies, Inc.
| 4 years |
| Alon Lazarus | M | 49 | 3 years | |
| Eric Sievers | M | 60 | 3 years | |
| Marilyn Olson | F | - |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 18 years |
| Guy Cipriani | M | 54 | 5 years | |
| Lawrence A. Romel | M | - |
Xcyte Therapies, Inc.
| - |
| Dennis J. Henner | M | 72 |
Xcyte Therapies, Inc.
| - |
| George M. Gould | M | 86 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 3 years |
| Jon Saxe | M | 88 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 4 years |
| Fred Kurland | M | 74 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 2 years |
| Jean Deleage | M | 83 |
Xcyte Therapies, Inc.
| 9 years |
| James Hall | M | 61 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 4 years |
| Scott Canute | M | 63 | - | |
| Mark McDade | M | 69 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 4 years |
| Helen Kim | F | 61 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 1 years |
| Mark Nathan Lampert | M | 56 | 1 years | |
| Eric Edward Baker | M | - |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | - |
| Brett L. Schmidli | M | 72 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 4 years |
| Gary W. Christianson | M | 69 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | - |
| Richard L. Jackson | M | 84 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 4 years |
| Mark W. Frohlich | M | 62 |
Xcyte Therapies, Inc.
| 4 years |
| Mark Bonyhadi | M | 70 |
Xcyte Therapies, Inc.
| 9 years |
| Peter J. Langecker | M | 73 |
Xcyte Therapies, Inc.
| 7 years |
| Stewart Craig | M | 63 |
Xcyte Therapies, Inc.
| 6 years |
| Stephen K. Burley | M | 66 | - | |
| Lyn D. Olson | M | 72 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 5 years |
| Robert D. Aubrey | M | - |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 17 years |
| Guy Ely | M | 71 |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | - |
| Ronald J. Helmhold | M | - |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | 11 years |
| Jane H. Tulloch | F | - |
Biomira, Inc.
Biomira, Inc. Medical/Nursing ServicesHealth Services Biomira, Inc. engages in the research and development of therapeutic products for the treatment of cancer. The company focuses on developing synthetic vaccines and novel strategies for cancer immunotherapy | - |
| Sergio Garcia-Rodriguez | M | 62 |
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | 5 years |
| Christopher German | M | 53 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 51 | 60.71% |
| Canada | 39 | 46.43% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert L. Kirkman
- Personal Network
